title: Re: final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.
authors.forename: David P
authors.initials: DP
authors.lastname: Wood
mesh_terms: D001500:BCG Vaccine / Q000008:administration & dosage*; D002291:Carcinoma, Papillary / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D001500:BCG Vaccine